E. Ohman J or Asset Management AB Buys 46,000 Shares of Bristol Myers Squibb Company $BMY

E. Ohman J or Asset Management AB boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 183.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,112 shares of the biopharmaceutical company’s stock after purchasing an additional 46,000 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Bristol Myers Squibb were worth $3,836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. CVA Family Office LLC raised its position in shares of Bristol Myers Squibb by 2.6% during the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 223 shares in the last quarter. MSH Capital Advisors LLC grew its position in Bristol Myers Squibb by 2.9% in the third quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock worth $362,000 after acquiring an additional 223 shares in the last quarter. Bell & Brown Wealth Advisors LLC increased its stake in Bristol Myers Squibb by 0.5% in the third quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company’s stock valued at $1,925,000 after acquiring an additional 224 shares during the last quarter. Harbor Investment Advisory LLC raised its position in Bristol Myers Squibb by 2.5% during the fourth quarter. Harbor Investment Advisory LLC now owns 9,322 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 224 shares in the last quarter. Finally, Addison Advisors LLC lifted its stake in Bristol Myers Squibb by 6.2% during the third quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $57.08 on Tuesday. The company’s fifty day simple moving average is $58.63 and its two-hundred day simple moving average is $51.94. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The firm has a market cap of $116.25 billion, a PE ratio of 16.55, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a report on Wednesday, December 3rd. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Scotiabank reaffirmed a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $61.41.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. and EU approvals expanded Opdivo’s label to include classical Hodgkin lymphoma across adult and pediatric groups, broadening the immunotherapy’s addressable market and strengthening BMY’s oncology growth runway. FDA Approves BMY’s Opdivo Label Expansion in Classical Hodgkin Lymphoma
• Positive Sentiment: New Camzyos (mavacamten) data presented at ACC.26 reinforce BMY’s leadership in obstructive hypertrophic cardiomyopathy (oHCM), supporting commercial adoption and longer-term revenue growth for the cardiology franchise. Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos Data at ACC.26
• Positive Sentiment: BMY expanded its collaboration with AI-drug developer insitro, nominating new targets in an ALS program — a sign of continued R&D productivity and de‑risking via external partnerships. insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
• Neutral Sentiment: Market commentary highlights BMY as an attractive high‑yield name for income investors, which can support demand for the stock in volatile markets but may limit upside if growth misses persist. Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty
• Neutral Sentiment: BMY’s CEO, Dr. Christopher S. Boerner, was appointed to Colgate‑Palmolive’s board — a reputational/leadership signal but not directly material to near‑term fundamentals. Colgate-Palmolive Taps Healthcare And Regional Marketing Expertise For Growth
• Negative Sentiment: Execution concerns remain after BMY’s February quarter missed EPS expectations (reported EPS below consensus) and FY‑2026 guidance that sits below some sell‑side forecasts — a near‑term headwind for the stock until growth from Opdivo/Camzyos and other programs is visible in results.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.